# Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

> **NCT04361253** · PHASE3 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 45 (actual)

## Conditions studied

- COVID
- Infectious Disease

## Interventions

- **BIOLOGICAL:** High-Titer COVID-19 Convalescent Plasma (HT-CCP)
- **BIOLOGICAL:** Standard Plasma (FFP)

## Key facts

- **NCT ID:** NCT04361253
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-30
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-06-30
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** Futility
- **Last updated:** 2021-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361253, "Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT04361253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*